Argenica Therapeutics Posts Positive Studies Results Required by US FDA for IND Application, Says Euroz Hartleys

MT Newswires Live

Sep 27, 2024

Argenica Therapeutics (ASX:AGN) posted positive results in several studies required by the US Food and Drug Administration for inclusion in the company's investigational new drug (IND) application to be submitted by the end of 2024, according to a Wednesday research note from Euroz Hartleys.

The company's in vivo micronucleus rats study confirmed ARG-007 does not impact genetic material, and a high maximum tolerated dose of 17.5 mg/kg was achieved, well above the therapeutic dose used in the current trial, the broker said.

AGN's phase 2 clinical trial in ischaemic stroke patients continues without safety issues and sufficient funding to complete the trial.

In addition, trial data showed that the drug has a unique mechanism of action and pharmacological benefits compared with competitors, the broker said.

Euroz Hartleys has a speculative buy recommendation on Argenica Therapeutics with a AU$1.40 price target.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2470792164"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2470792164\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2470792164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-27 07:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470792164","market":"hk","top_or_hot":-1,"title":"Argenica Therapeutics Posts Positive Studies Results Required by US FDA for IND Application, Says Euroz Hartleys","media":"MT Newswires Live","content":"<html><body><p> Argenica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:AGN) posted positive results in several studies required by the US Food and Drug Administration for inclusion in the company's investigational new drug (IND) application to be submitted by the end of 2024, according to a Wednesday research note from <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>The company's in vivo micronucleus rats study confirmed ARG-007 does not impact genetic material, and a high maximum tolerated dose of 17.5 mg/kg was achieved, well above the therapeutic dose used in the current trial, the broker said.</p><p>AGN's phase 2 clinical trial in ischaemic stroke patients continues without safety issues and sufficient funding to complete the trial.</p><p>In addition, trial data showed that the drug has a unique mechanism of action and pharmacological benefits compared with competitors, the broker said.</p><p>Euroz Hartleys has a speculative buy recommendation on Argenica Therapeutics with a AU$1.40 price target.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenica Therapeutics Posts Positive Studies Results Required by US FDA for IND Application, Says Euroz Hartleys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenica Therapeutics Posts Positive Studies Results Required by US FDA for IND Application, Says Euroz Hartleys\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-27 07:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Argenica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:AGN) posted positive results in several studies required by the US Food and Drug Administration for inclusion in the company's investigational new drug (IND) application to be submitted by the end of 2024, according to a Wednesday research note from <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>The company's in vivo micronucleus rats study confirmed ARG-007 does not impact genetic material, and a high maximum tolerated dose of 17.5 mg/kg was achieved, well above the therapeutic dose used in the current trial, the broker said.</p><p>AGN's phase 2 clinical trial in ischaemic stroke patients continues without safety issues and sufficient funding to complete the trial.</p><p>In addition, trial data showed that the drug has a unique mechanism of action and pharmacological benefits compared with competitors, the broker said.</p><p>Euroz Hartleys has a speculative buy recommendation on Argenica Therapeutics with a AU$1.40 price target.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470792164","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470792164","pubTimestamp":1727392965,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Argenica Therapeutics  posted positive results in several studies required by the US Food and Drug Administration for inclusion in the company's investigational new drug  application to be submitted by the end of 2024, according to a Wednesday research note from Euroz Hartleys.The company's in vivo micronucleus rats study confirmed ARG-007 does not impact genetic material, and a high maximum tolerated dose of 17.5 mg/kg was achieved, well above the therapeutic dose used in the current trial, the broker said.AGN's phase 2 clinical trial in ischaemic stroke patients continues without safety issues and sufficient funding to complete the trial.In addition, trial data showed that the drug has a unique mechanism of action and pharmacological benefits compared with competitors, the broker said.Euroz Hartleys has a speculative buy recommendation on Argenica Therapeutics with a AU$1.40 price target.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","IND.AU":"Industrial Minerals Ltd","LENZ":"Therapeutics","BK4139":"生物科技","AGN.AU":"Argenica Therapeutics Ltd","BK7095":"多种金属与采矿"},"translate_title":"Euroz Hartleys表示，Argenica Therapeutics公布了美国FDA IND申请所需的积极研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IND.AU":1,"LENZ":1,"AGN.AU":0.9},"content_text":"Argenica Therapeutics (ASX:AGN) posted positive results in several studies required by the US Food and Drug Administration for inclusion in the company's investigational new drug (IND) application to be submitted by the end of 2024, according to a Wednesday research note from Euroz Hartleys.The company's in vivo micronucleus rats study confirmed ARG-007 does not impact genetic material, and a high maximum tolerated dose of 17.5 mg/kg was achieved, well above the therapeutic dose used in the current trial, the broker said.AGN's phase 2 clinical trial in ischaemic stroke patients continues without safety issues and sufficient funding to complete the trial.In addition, trial data showed that the drug has a unique mechanism of action and pharmacological benefits compared with competitors, the broker said.Euroz Hartleys has a speculative buy recommendation on Argenica Therapeutics with a AU$1.40 price target.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}